Pulse Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on March 21, 2023, covering events occurring on March 17, 2023. The Company is a Delaware corporation with its principal executive offices in Hayward, California, and its common stock trades on The Nasdaq Stock Market under the symbol "PLSE".
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The report focuses exclusively on a corporate action regarding debt restructuring.
Material Changes
The Company entered into the First Amendment to a Loan Agreement previously established with Robert W. Duggan on September 20, 2022. The material change effected by this amendment is the extension of the scheduled maturity date of the loan to September 30, 2024.
Outlook, Risks, and Management Commentary
Management commentary is limited to the disclosure of the amendment terms. The filing does not contain forward-looking guidance, updated risk factors, or discussion of contingencies beyond the debt extension. The full text of the First Amendment is attached as Exhibit 10.1.
Key Facts for Investor Verification
- The loan maturity date with Robert W. Duggan has been extended to September 30, 2024.
- The original Loan Agreement was dated September 20, 2022.
- The filing does not disclose the principal amount, interest rate, or other specific terms of the loan; investors should review Exhibit 10.1 for complete details.
- No financial performance data is included in this specific report.